Guide up, stock down
Pfizer raised full-year revenue and EPS guidance on non-COVID growth, while the stock moved moderately lower on the day.
Previous verdicts for PFE
- AI Search: Pfizer Edges Higher as 2026 Outlook Headlines Conflict — 2026-11-09
- AI Search: DZ Bank Downgrades Pfizer to Hold as Shares Fall Sharply — 2026-11-06
- Pfizer drops sharply — 2026-10-28
- AI Search: Pfizer grinds toward 52-week high as buyers lean on bull case — 2026-10-20
- AI Search: Pfizer Climbs Sharply on $500M Enodia Therapeutics Partnership — 2026-10-14
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works